Sobi's Annual Report 2015 is themed “A new chapter of our story”. The integrated report summarises the business as well as financial highlights for 2015, and gives a deeper insight into the company’s strategic agenda and its patient-centric innovation model. The 2015 Annual Report is available both in print and as an interactive online version.
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the first quarter 2014. Revenues totalled SEK 573.3 M (528.5), an increase of 8 per cent. The Partner Products portfolio was a highlight, with 70 per cent growth compared to the first quarter last year.
Sobi had an eventful year in 2013 with strong operating performance and significant pipeline progress. Revenues in the quarter rose by 29 per cent and in the year by 13 per cent compared to the previous year. Our gross margin increased substantially, and we strengthened our company financially through both positive cash flow and improved operating profit.